

DESCRIPTION

| | |
|---------------------------|--|
| Species Reactivity | Human |
| Specificity | Detects human LRRC32/GARP in ELISAs. |
| Source | Monoclonal Rat IgG _{2A} Clone # 855151 |
| Purification | Protein A or G purified from hybridoma culture supernatant |
| Immunogen | Chinese hamster ovary cell line CHO-derived recombinant human LRRC32/GARP Met1-Asn627 Accession # Q14392 |
| Conjugate | Phycoerythrin Excitation Wavelength: 488 nm Emission Wavelength: 565-605 nm |
| Formulation | Supplied in a saline solution containing BSA and Sodium Azide. See Certificate of Analysis for details. *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions. |


APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

| | Recommended Concentration | Sample |
|-----------------------|----------------------------------|-----------|
| Flow Cytometry | 10 μ L/10 ⁶ cells | See Below |

DATA

Flow Cytometry



Detection of LRRC32/GARP in Human PBMCs stimulated to induce Tregs by Flow Cytometry. Human peripheral blood mononuclear cells (PBMCs) stimulated to induce Regulatory T Cells (Tregs) treated with 10 μ g/mL Anti-CD3, 5 μ g/mL Anti-CD28, 10 ng/mL Recombinant Human TGF- β 1 (Catalog # 240-B), and 20 ng/mL Recombinant Human IL-2 (Catalog # 202-IL) for 48 hours were stained with Mouse Anti-Human LAP TGF- β 1 APC-conjugated Monoclonal Antibody (Catalog # FAB2463A) and either (A) Rat Anti-Human LRRC32/GARP PE-conjugated Monoclonal Antibody (Catalog # FAB6055P) or (B) Rat IgG_{2A} Phycoerythrin Isotype Control (Catalog # IC006P). View our protocol for [Staining Membrane-associated Proteins](#).

PREPARATION AND STORAGE

| | |
|--------------------------------|--|
| Shipping | The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage | Protect from light. Do not freeze. <ul style="list-style-type: none"> 12 months from date of receipt, 2 to 8 °C as supplied. |

BACKGROUND

Leucine-rich repeat protein 32 (LRRC32), also known as GARP (glycoprotein A repetitions predominant), is an 80 kDa type I transmembrane glycoprotein (1). Mature human LRRC32 consists of a 608 amino acid (aa) extracellular domain (ECD) that contains 22 leucine-rich repeats, a 21 aa transmembrane segment, and a 14 aa cytoplasmic domain (2, 3). Within the ECD, human LRRC32 shares approximately 80% aa sequence identity with mouse and rat LRRC32. LRRC32 is widely expressed during embryogenesis and on adult platelets (4, 5). Human LRRC32 is identified as a lineage specific key receptor for human T cells. It is selectively expressed on activated FOXP3⁺ regulatory T cells (Treg) (6-10). LRRC32 expression promotes the acquisition of a Treg phenotype including reduced cellular proliferation, reduced cytokine secretion, and the capacity to suppress the proliferation of naïve T cells (6-8). LRRC32 binds directly to the TGF- β latency associated peptide (LAP) and tethers latent TGF- β on the surface of activated Treg cells (9, 10). The presentation of TGF- β on Tregs contributes to their ability to suppress naïve T cell proliferation (11).

References:

1. Battaglia, M. and M.G. Roncarolo (2009) *Eur. J. Immunol.* **39**:3296.
2. Ollendorff, V. *et al.* (1994) *Cell Growth Differ.* **5**:213.
3. Bella, J. *et al.* (2008) *Cell Mol Life Sci.* **65**:2307.
4. Roubin, R. *et al.* (1996) *Int. J. Dev. Biol.* **40**:545.
5. Macaulay, I.C. *et al.* (2007) *Blood* **109**:3260.
6. Wang, R. *et al.* (2008) *PLoS ONE* **3**:e2705.
7. Wang, R. *et al.* (2009) *Proc. Natl. Acad. Sci.* **106**:13439.
8. Probst-Kepper, M. *et al.* (2009) *J. Cell. Mol. Med.* **13**:3343.
9. Tran, D.Q. *et al.* (2009) *Proc. Natl. Acad. Sci.* **106**:13445.
10. Stockis, J. *et al.* (2009) *Eur. J. Immunol.* **39**:3315.
11. Vignali, D.A. *et al.* (2008) *Nat. Rev. Immunol.* **8**:523.